Abstract 15315: SGLT2 Inhibitor Ertugliflozin Decreases Elevated Intracellular Sodium, Improves Myocardial Energetics and Enhances Function in Metabolic Heart Disease

Dominique Croteau,Tomas Baka,Sara Young,Huamei He,David R. Pimentel,Marcello Panagia,James A. Balschi,Wilson S. Colucci,Ivan Luptak

Abstract 15315: SGLT2 Inhibitor Ertugliflozin Decreases Elevated Intracellular Sodium, Improves Myocardial Energetics and Enhances Function in Metabolic Heart Disease

2020

Dominique Croteau
Tomas Baka
Sara Young
Huamei He
David R. Pimentel
Marcello Panagia
James A. Balschi
Wilson S. Colucci
Ivan Luptak

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic drugs of great interest in cardiology due to their improvement of heart failure outcomes independent of diabetes. As ...

Keywords:

Pharmacology
SGLT2 Inhibitor
intracellular sodium
Heart failure
Ion transporter
Heart disease
Energetics
myocardial energetics
Medicine
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations